Citigroup Reiterates Buy Rating, $60 PT on CVS Caremark Corporation
In a report published Monday, Citigroup reiterated its Buy rating and $60.00 price target on CVS Caremark Corporation (NYSE: CVS).
Citigroup noted, “We expect investors to focus on: 1) WAG/ESRX script retention; 2) the 2013 PBM selling season; 3) PBM streamlining initiatives; 4) opportunities to drive utilization, incl. Maintenance Choice (MC), generics, and healthcare reform; 5) specialty; 6) int'l expansion; and 7) capital allocation. CVS's unique business model continues to gain traction, and we anticipate optimistic 2013 guidance to be provided. CVS is Buy-rated and on Citi's Top Picks Live! list.”
CVS Caremark Corporation closed on Friday at $47.23.
Latest Ratings for CVS
|Oct 2016||UBS||Initiates Coverage on||Buy|
|Oct 2016||Bank of America||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.